Control of Voltage-gated Potassium Channel Kv2.2 Expression by Pyruvate-Isocitrate Cycling Regulates Glucose-stimulated Insulin Secretion* 

Received for publication, June 5, 2013. Published, JBC Papers in Press, June 20, 2013, DOI 10.1074/jbc.M113.491654

Mette V. Jensen‡§, Jonathan M. Haldeman†‡, Hengtao Zhang‡, Danhong Lu†, Mark O. Huising‡¶, Wylie W. Vale†, Hans E. Hohmeier†*, Paul Rosenberg†*, and Christopher B. Newgard‡¶

From the ‡Sarah W. Stedman Nutrition and Metabolism Center and Duke Institute of Molecular Physiology, Departments of §Pharmacology and Cancer Biology and ¶Medicine, Duke University Medical Center, Durham, North Carolina 27704 and ‡¶Clayton Foundation Laboratories for Peptide Biology and **Salk Center for Nutritional Genomics, The Salk Institute for Biological Studies, La Jolla, California 92037

**This work was supported, in whole or in part, by National Institutes of Health Grants DK42583 (to C. B. N.) and DK026741 (to W. W. V. and M. O. H.). This work was also supported by the Juvenile Diabetes Research Foundation (to M. O. H.).

†To whom correspondence should be addressed: Sarah W. Stedman Nutrition and Metabolism Center, Duke University Independence Park Facility, 4321 Medical Park Dr., Durham, NC 27704. Tel.: 919-668-6059; Fax: 919-477-0632; E-mail: chris.newgard@duke.edu.

‡ The abbreviations used are: GSIS, glucose-stimulated insulin secretion; ICDc, cytosolic NADP-dependent isocitrate dehydrogenase; ICIC, mitochondrial isocitrate dehydrogenase; KATP, ATP-sensitive potassium; Kv, voltage-gated potassium; MIP, mouse insulin promoter; O/P, oleate/palmitate; ScTx1, stromatoxin1; SUMO, small ubiquitin-like modifier; qRT-PCR, quantitative RT-PCR; Ad, adenosinergic; pF, picofarad.

Glucose-stimulated insulin secretion (GSIS)2 is essential for control of metabolic fuel homeostasis, and its impairment is a key element of β-cell failure in type 2 diabetes. The canonical mechanistic model of GSIS holds that glucose metabolism in β-cells leads to ATP-mediated closure of KATP channels, which in turn activates voltage-gated L-type Ca2+ channels, resulting in Ca2+ influx to trigger insulin secretion (for reviews, see Refs. 1 and 2).

It has become increasingly clear that KATP channel-independent pathways also contribute to GSIS (3–5). Our laboratory and others have implicated pathways of pyruvate exchange with tricarboxylic acid cycle intermediates (“pyruvate cycling”) in GSIS (6–23), and work from our group has demonstrated that the pyruvate-isocitrate cycle has a particularly prominent role both in both primary islets and β-cell lines (8, 10, 11, 23). The pyruvate-isocitrate cycle begins with anaplerotic entry of pyruvate into the mitochondria via pyruvate carboxylase. The product of the pyruvate carboxylation reaction, oxaloacetate, undergoes mitochondrial metabolism to produce citrate and isocitrate, which are subsequently exported out of the mitochondria via the citrate-isocitrate carrier (CIC). Isocitrate is then converted to α-ketoglutarate in a reaction catalyzed by cytosolic NADP-dependent isocitrate dehydrogenase (ICIC). Consistent with this model, silencing of either CIC or ICIC causes marked impairment of GSIS in β-cell lines and primary rat islets (11, 23). Knockdown of the mitochondrial α-ketoglutarate/malate antiporter also inhibits GSIS (10), suggesting that completion of the pyruvate-isocitrate cycle may involve re-entry of α-ketoglutarate into the mitochondria (8). The molecular mechanisms linking pyruvate-isocitrate cycling activity to GSIS remain unresolved.

Background: Pyruvate-isocitrate cycling is involved in control of glucose-stimulated insulin secretion (GSIS), but the underlying mechanisms are unknown.

Results: Pyruvate-isocitrate cycling controls expression of the voltage-gated potassium channel family member Kv2.2 in islet cells.

Conclusion: Pyruvate-isocitrate cycling maintains Kv2.2 expression, allowing it to serve as a negative regulator of Kv channel activity.

Significance: Kv2.2 is a potential new target for reversing β-cell dysfunction of type 2 diabetes.
Glucose metabolism-induced closure of \( K_{\text{ATP}} \) channels and membrane depolarization are counteracted by repolarization mediated by voltage-gated potassium (Kv) channels. Kv channels belong to the six-transmembrane family of K⁺ channels, and to date, members of five subfamilies (Kv1, -2, -3, -6, and -9) have been identified in primary \( \beta \)-cells (for reviews, see Refs. 2 and 24). Of these, members of the Kv1, Kv2, and Kv3 subfamilies form tetrameric functional channels as homo- and heteromultimers. In contrast, members of the Kv6 and Kv9 subfamilies encode “silent subunits” that do not form functional homomultimers but modulate Kv2 and Kv3 channel activities when expressed in heterologous systems (25, 26). In addition to these interactions, Kv channel activities can be modified by association with regulatory \( \beta \)-subunits (27–29) or by post-translational modifications such as phosphorylation, ubiquitination, SUMOylation, and palmitoylation (30–33).

The specific roles of the various subtypes of Kv subunits in control of insulin secretion are not fully understood. Kv2.1 is considered the dominant Kv channel species in rodent \( \beta \)-cells, and pharmacologic inhibition of Kv2.1 enhances GSIS (34–37). Furthermore, Kv2.1-null mice show improved glucose tolerance with reduced fasting glucose as a consequence of enhanced insulin secretion (38). However, \( \beta \)-cells from Kv2.1-null mice have residual Kv current (38), demonstrating that channels other than Kv2.1 are active in these cells. Furthermore, although abundant Kv2.1 protein and channel activity are observed in human islets (37, 39), Kv2 inhibitors do not affect human \( \beta \)-cell electrical function or insulin secretion (40), an observation concordant with mathematical modeling studies (41). Immunolocalization studies suggest that Kv2.2 is expressed primarily in islet \( \delta \)-cells (42), but these studies do not rule out expression in other islet cell types.

NADPH produced in the ICDc-catalyzed reaction is a potential coupling factor derived from pyruvate-isocitrate cycling activity (8, 22). Consistent with this idea, a linear correlation between NADPH:NADP ratio and GSIS has been observed, and suppression of pyruvate-isocitrate cycling activity and GSIS by siRNA-mediated silencing of CIC, ICDc, or \( \alpha \)-ketoglutarate/malate antiporter decreases the NADPH:NADP ratio (10, 11, 23). Also, NADPH stimulates insulin granule exocytosis when added to permeabilized \( \beta \)-cells (11, 43). NADPH has been suggested to be a direct regulator of plasma membrane electrical potential by interaction with the NADPH-dependent oxidoreductase-like motif of Kv channel \( \beta \)-subunits, ostensibly resulting in inhibition of Kv2.1 channel activity and enhanced GSIS (44).

In this study, we investigated the possible linkages between pyruvate-isocitrate cycling and Kv channel expression and activity. Surprisingly, although Kv2.1 expression was unchanged, Kv2.2 channel expression was reduced rather than increased in multiple models of impairment of pyruvate-isocitrate cycling and GSIS. siRNA-mediated suppression of Kv2.2 expression impaired GSIS in 832/13 cells, whereas restoration of Kv2.2 in the background of reduced ICDc expression rescued impaired GSIS in both insulinoma cells and primary rat islets. Co-overexpression of Kv2.1 and Kv2.2 in 832/13 cells impaired the increase in outward K⁺ current observed with Kv2.1 overexpression alone, and co-immunoprecipitation studies demonstrated a physical interaction between the two proteins. Finally, chronic exposure of 832/13 cells to elevated levels of fatty acids, a maneuver that causes impairment of GSIS and loss of glucose regulation of pyruvate cycling activity (6), resulted in suppression of Kv2.2 but not Kv2.1 expression. Taken together, our data support a model in which key function of the pyruvate-isocitrate cycle is to maintain expression of Kv2.2 at levels required for it to serve as a negative regulator of Kv2.1 channel activity in \( \beta \)-cells. Our findings point to Kv2.2 as a potential new target for reversing the \( \beta \)-cell dysfunction observed in type 2 diabetes.

**EXPERIMENTAL PROCEDURES**

**Reagents**—All reagents and solutions were obtained from Sigma-Aldrich unless otherwise indicated.

**Cell Lines and Primary Islets**—The highly glucose-responsive insulinoma cell line 832/13 was derived from INS-1 cells (45) via a transfection-selection strategy and cultured as described previously (46). Rat primary islets were harvested from male Sprague-Dawley rats weighing ~300 g under a protocol approved by the Duke University Institutional Animal Care and Use Committee and cultured as described previously (12). We used both MIP-GFP (47) and MIP-Cherry² mice to study gene expression in purified primary mouse \( \beta \)-cells. A mouse \( \delta \)-cell reporter (B6(Cg)-Ssttm1(cre/ERT2)Zjh/J) was obtained from The Jackson Laboratory (Sacramento, CA), and nuclear localization of the Cre/ERT2 fusion was achieved by continuous tamoxifen administration in chow (250 mg/kg; custom formulation; Harlan Teklad, Madison WI). Glucagon-Cre mice (49) were obtained from Mutant Mouse Regional Resource Centers (Chapel Hill, NC). Both Cre lines were crossed to tdTomato reporter mice (B6.Cg-Gt(Rosa)26Sortm14(CAG-tdTomato)Hze/J; The Jackson Laboratory) to visualize Cre recombinase activity. All mouse protocols were approved by the Salk Institute for Biological Studies Institutional Animal Care and Use Committee, and mouse islets were isolated and cultured as described (50).

**Glucose-stimulated Insulin Secretion**—Insulin secretion from 832/13 cells and rat primary islets (~20 islets per incubation) was measured as described previously (7).

**Lipotoxicity Studies**—For studies of lipid-induced impairment of GSIS in 832/13 cells, a 10 \( \mu \)M oleate/palmitate (O/P; 2:1 molar ratio) stock solution complexed to 10% fatty acid-free bovine serum albumin (BSA) was prepared as described (6). The O/P solution was added to cells at a final concentration of 1 \( \mu \)M in complete medium for 24 or 48 h as indicated. In parallel, control cells were treated with 1% BSA. Subsequent GSIS analyses were performed in the absence of O/P.

**Adenovirus Design and Construction**—A human Kv2.2 cDNA/pENTR223 clone was obtained from Open Biosystems (Lafayette, CO), and human Kv2.1/pENTR223 was obtained from the Dana-Farber/Harvard Cancer Center DNA Resource Core at Harvard Medical School, Boston, MA (clone HsCD003992988). Both constructs were inserted into the pAd/CMV/V5-DEST gateway vector (Invitrogen) using recombination-based cloning according to the manufacturer’s recommendations. The viral vector was subsequently sequenced,

³ M. O. Huising, manuscript in preparation.
digested with Pacl and transfected into the 293A cell line (Invitrogen) to generate viral stocks. Adenoviruses containing siRNA sequences specific for Kv2.2 and Kv2.1 (sequences described below) were constructed using vectors EH006 and pJM17 as described previously (51). After amplification in 293 cells, adenoviruses were purified by CsCl gradient, and titers of pure viral preparations were determined by measurement of $A_{260}$ (51, 52).

**RNAi-mediated Gene Silencing and Kv2.2 Overexpression in Insulinoma Cells**—832/13 cells cultured in 12-well plates (40% confluence) were transfected with siRNA duplexes (Integrated DNA Technologies, Coralville, IA) for 24 h using Dharmafect Transfection Reagent 1 (Dharmacon, Lafayette, CO) at a final concentration of 50 nM. After an additional 48 h in culture, cells were used for insulin secretion, gene expression analysis (qRT-PCR), or patch clamp studies. The silCdc target sequence was GTA TGA TGG ACG CCT AAG A (11), and the siCtc target sequence was GACCGAATACGTGAAGACT (23).

Kv2.2 siRNA targets were GATA CCA TTC TTC TAG AAG A and CCA ACA AGT CCT ACG A. The Kv2.1 siRNA target sequences were CAG ATG AAC GAG GAG CTG A and CCA ACA AGT CTT ACG AGA A. The Kv2.2 siRNA targets were used for insulin secretion, gene expression analysis (qRT-PCR), or patch clamp studies. The siICDc target sequence was GTA CCA TTC TTC TAG AAG A and CAG ATG AAC GAG GAG CTG A.

**Co-immunoprecipitation of Kv2.1 and Kv2.2**—For co-immunoprecipitation assays, 832/13 cells were seeded on small pieces of coverslips (for RNAi experiments, only GFP-positive cells were picked) and transfected to a Warner chamber perfused with a solution consisting of 140 mM NaCl, 2 mM MgCl$_2$, 2.5 mM CaCl$_2$, 2 mM glucose, and 10 mM HEPES, pH 7.4. Pipettes were pulled from borosilicate glass (Sutter P-87) with a resistance between 2.5 and 4 megohms when filled with pipette solution containing 30 mM KCl, 95 mM potassium gluconate, 5 mM Na$_2$ATP, 10 mM HEPES, 11 mM EGTA, 1 mM CaCl$_2$, and 2 mM MgSO$_4$, pH 7.2. The cells were held at −80 mV, and the K$^+$ currents were activated by depolarizing steps from −80 to 60 mV with an interval of 10 mV for a 2-s duration. For siRNA experiments, measurements were repeated after addition of glucose to a final concentration of 12 mM. Whole cell currents were recorded using an Axopatch 200B amplifier with a sample rate of 5 kHz. The junction potential was nulled before the pipette contacted the cell, and no further correction was done. The whole cell current recordings from those cells having a seal resistance larger than 1 gigaohm were used for final analysis. Normalized current-voltage relationships were determined by plotting currents at the end of the test as pulse versus voltage.

**Immunoblot Analyses**—832/13 cells were seeded in P150 plates at 80% confluence and either left untreated or transduced with AdCMV-hKv2.2 for 16 h followed by medium change and an additional 24-h incubation. The viral dose applied was $35 \times 10^{12}$ viral particles/plate in 20 ml of medium, which is 6.3 and 3.2 times higher per cell than the doses used for silCdc rescue experiments. Cell surface proteins were biotinylated using the Scientific Cell Surface Protein Isolation kit from Thermo Scientific (Rockford, IL). After cell lysis, labeled surface proteins were affinity-purified using agarose-linked avidin and subsequently eluted in 300 μl of SDS-PAGE sample buffer (Invitrogen) containing 50 mM DTT for 60 min at room temperature. Eluted cell surface proteins (30 μl) were separated on 4–12% NuPAGE SDS-polyacrylamide gels (Invitrogen) and transferred to polyvinylidene difluoride membranes (Invitrogen). Blots were blocked with 5% BSA and 1% TBS with Tween 20 for 45 min and incubated overnight with either anti-Kv2.2 antibody (Alomone Labs, Jerusalem, Israel; diluted 1,000× in 1% polyvinylpyrrolidone) or anti-V5 antibody (Invitrogen; diluted 5,000× in 1% polyvinylpyrrolidone). Donkey horseradish peroxidase-conjugated anti-rabbit IgG (Kv2.2; 1:10,000) or sheep horseradish peroxidase-conjugated anti-mouse IgG (for V5; 1:10,000) was used as secondary antibody (GE Healthcare) prior to ECL detection.

**Co-immunoprecipitation of Kv2.1 and Kv2.2**—For co-immunoprecipitation, 5 × 10$^6$ 832/13 cells were lysed in 0.5 ml of cold lysis buffer containing HALT protease inhibitors (Thermo Scientific), 150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 1 mM EGTA, and 1% Triton X-100. Lysates were incubated on ice for 30 min and centrifuged at 10,000 × g for 15 min at 4 °C. The
supernatant was immunoprecipitated overnight with 2 μg of anti-KV2.2 (Alomone Labs) or anti-KV2.1 (QED Bioscience, San Diego, CA) antibody and either rabbit (KV2.2) or mouse (KV2.1) IgG-TrueBlot IP beads (eBioscience, San Diego, CA). Precipitated proteins were eluted according to the manufacturer’s protocol and detected by immunoblot as described above. Blots were incubated with primary antibodies against KV2.2 (Alomone) and KV2.1 (QED Bioscience; 3 μg/ml in 1% polyvinylpyrrolidone) followed by incubation with Alexa Fluor 680 anti-rabbit (Invitrogen) and IRDye 800CW anti-mouse (LI-COR Biosciences, Lincoln, NE) fluorescent secondary antibodies. Blots were then imaged using the LI-COR Odyssey CLx.

**RESULTS**

**Kv2.2 mRNA Levels Are Lowered in 832/13 Cells with Suppressed Pyruvate-Isocitrate Cycling Activity**—Clear correlations between pyruvate cycling and NADPH production (7, 11, 23) and between NADPH production and insulin secretion (8, 11, 43) have been established in recent years. There are also data suggesting that NADPH regulates Kv channel activity in β-cells purportedly by interaction with the NADPH-dependent oxidoreductase-like motif of Kv channel β-subunits (44). To further investigate possible cause and effect relationships among these variables, we began to assess the impact of manipulation of pyruvate-isocitrate cycling activity on Kv channel expression and function. Our prior studies demonstrating a role for pyruvate-isocitrate cycling in regulation of GSIS used siRNAs specific for ICDe or CIC to suppress pyruvate-isocitrate cycling activity, resulting in clear impairment in GSIS (11, 23). Here, treatment of INS-1-derived 832/13 cells with siICDe and siCIC duplexes resulted in 69 ± 1 and 60 ± 7% decreases in ICDe and CIC mRNA levels, respectively, with no effect on Kv2.1 mRNA levels (Fig. 1, A and B). In contrast, siRNA-mediated suppression of either ICDe or CIC caused a significant decrease in Kv2.2 expression (60 ± 4 and 36 ± 7% reduction, respectively; p < 0.01; Fig. 1, A and B).

**Suppression of Kv2.2 but Not Kv2.1 Expression in 832/13 Cells Impairs GSIS**—We next studied the direct effects of silencing of Kv2.1 or Kv2.2 expression on insulin secretion using siKv2.1,
silKv2.2, or siControl duplexes in 832/13 cells. Silencing of Kv2.1 by 61 ± 7% had no significant effect on GSIS (p > 0.3), whereas a 72 ± 5% knockdown of Kv2.2 mRNA levels caused a clear impairment (p < 0.01) (Fig. 1, C and D). Results were confirmed with independent Kv2.1- and Kv2.2-specific siRNA duplexes (data not shown).

Kv2.2 Overexpression Rescues the Inhibitory Effects of siICdc on GSIS in 832/13 Cells—As a tool for manipulating Kv2.2 expression, we constructed an adenovirus containing the human Kv2.2 cDNA fused to a C-terminal V5 epitope tag (AdCMV-hKv2.2). Immunoblot analyses with an antibody to the V5 epitope detected two major bands of ~100 and 130 kb in cell membrane fractions from AdCMV-hKv2.2-treated 832/13 cells but not from untreated cells (Fig. 2A). These results were confirmed by blotting with an anti-Kv2.2 antibody (Fig. 2B). The deduced size of Kv2.2 is 102.4 kDa (V5-tagged Kv2.2 is ~106 kDa), and we hypothesize that the lower of the two bands is the native Kv2.2 protein, whereas the higher band may represent a post-translationally modified form of the protein. Consistent with this interpretation, a similar, major band at 140 kDa has been shown to represent phosphorylated Kv2.2 protein in brain membrane fractions (30). Our data show that treatment of 832/13 cells with increasing doses of AdCMV-hKv2.2 resulted in a dose-dependent increase in Kv2.2 expression (Fig. 2C–E).
of 832/13 cells with AdCMV-hKv2.2 results in expression of proteins of physiologically relevant sizes that are recognized by the Kv2.2 antibody and localized to the cell membrane.

Using the AdCMV-hKv2.2 adenovirus, we next investigated whether overexpression of Kv2.2 can rescue the impairment of GSIS caused by reduced ICDc expression. For this purpose, 832/13 cells were transfected with siICDc or siControl duplexes or left untreated for 72 h. For the last 40 h of the experiment, cells were either transduced with AdCMV-hKv2.2 (Fig. 2, C–F). To limit the extent of overexpression of Kv2.2 to reasonable levels, we tested the impact of different doses of the AdCMV-Kv2.2 adenovirus on Kv2.2 protein expression in total cell extracts as shown in Fig. 2C. The lowest doses of AdCMV-Kv2.2 that caused detectable increases in Kv2.2-V5 protein were 0.1 and 0.2 μl of purified virus (Fig. 2C). These doses of AdCMV-hKv2.2 were 6.3 and 3.2 times lower than the doses used for the cell membrane immunoblot studies in Fig. 2, A and B, and gave rise to 10 ± 2- and 45 ± 7-fold increases in Kv2.2 mRNA levels relative to AdCMV-βgal-treated cells (Fig. 2D). siICDc treatment resulted in a 66 ± 2% decrease in ICdc mRNA levels, and the degree of knockdown was unaffected by the presence of AdCMV-hKv2.2 virus (Fig. 2E). ICdc knockdown alone resulted in 38% impairment in insulin secretion at 12 mM glucose relative to non-transfected and siControl-treated cells (p = 0.006 and p = 0.004; Fig. 2F). This impairment was partially reversed in cells treated with the low dose (0.1 μl) of AdCMV-hKv2.2 (p = 0.004 compared with β-gal/siICDc) and completely rescued to the level of control cells by the higher dose of AdCMV-hKv2.2 (0.2 μl). These experiments demonstrate that impaired GSIS in siICDc-treated 832/13 cells can be fully rescued by expression of Kv2.2. In contrast, overexpression of hKv2.1 did not rescue the inhibitory effects of Ad-siICDc on GSIS.

Kv2.2 Expression Is Reduced by Chronic Exposure to Elevated Fatty Acid Levels—We and others have demonstrated that chronic exposure of insulinoma cells or primary islets to elevated concentrations of fatty acids causes impairment of GSIS (6, 53–56). We have also shown that chronic lipid exposure impairs normal regulation of pyruvate cycling activity by glucose (6). We therefore measured the impact of excess fatty acids on Kv2.1 and Kv2.2 expression. Exposure of 832/13 cells to 1 mM O/P (2:1) complexed to albumin for 24 or 48 h caused 45 ± 4 and 31 ± 5% decreases in Kv2.2 mRNA levels, respectively, compared with BSA-cultured controls (p = 0.0009 and p = 0.007; Fig. 3A). In contrast, the same lipid exposure caused a small decrease in Kv2.1 at 24 h (22 ± 5%, p = 0.04) but had no effect at 48 h (p = 0.7) (Fig. 3B). Consistent with our prior work (6), 24 h of exposure to O/P increased basal insulin secretion compared with BSA-treated control cells (p < 0.01), whereas 48 h of O/P exposure led to both an increase in secretion at basal glucose (p < 0.001) and a decrease in insulin secretion at stimulatory glucose (p < 0.001; Fig. 3C). The lack of effect of

FIGURE 3. Kv2.2 mRNA expression is reduced by chronic exposure to elevated fatty acids. 832/13 cells were cultured for a total of 3 days and exposed to a mixture of 1 mM O/P complexed to BSA in a 2:1 ratio or to BSA alone for the final 24 or 48 h as indicated. qRT-PCR measurement of Kv2.1 expression (A) and Kv2.2 expression (B) is shown. C, GSIS analysis. Data for all panels represent six independent experiments, each performed in duplicate. *, p < 0.001; #, p < 0.01; @, p < 0.05. Error bars represent S.E. uU, microunits.
**Pyruvate Cycling and Kv2.2 Regulate Insulin Secretion**

**FIGURE 4. Kv2.2 is expressed in α-, β-, and δ-cells of the intact rodent islet.** A–D, dissociated mouse islet cells were sorted based on expression of fluorescent proteins and tested for Kv2.2 expression by qRT-PCR analyses. A, transgenic reporter mouse model that expresses GFP under control of the insulin promoter (MIP-GFP). B, transgenic reporter mouse model that expresses mCherry under control of the insulin promoter. C, the α-cell reporter line, glucagon-Cre. D, the δ-cell reporter line, SST-CreER. Error bars represent S.E. pos., positive; neg., negative.

fatty acids on insulin secretion at stimulatory glucose at 24 h despite a decrease in Kv2.2 mRNA at this time point may reflect a delay in turnover of the Kv2.2 protein. We were unable to test this possibility directly due to limitations in sensitivity of our antibody for detection of endogenous Kv2.2 protein. Kv2.2 is Expressed in α-, β-, and δ-Cells of the Intact Islet—Two reports have suggested that Kv2.2 is mainly expressed in δ-cells of the intact islet and that expression may either be lacking or very low in β-cells (42, 57). We note first that Kv2.2 is readily expressed in our well differentiated β-cell line 832/13 (Figs. 1–3), and manipulation of its expression affects GSIS, suggesting an intrinsic role for Kv2.2 in the β-cell. Nevertheless, to address this issue more completely, we investigated expression of Kv2.2 in FACS-sorted α-, β-, and δ-cell populations of the mouse islet (Fig. 4). In Fig. 4, A and B, we used transgenic β-cell reporter mouse models that express GFP and mCherry, respectively, under control of the mouse insulin promoter (47). In agreement with earlier studies (50, 58), we observed that only ~50% of the β-cells of the MIP-GFP line express GFP, explaining the relatively modest enrichment (~1.5-fold) of insulin expression in the GFP-positive fraction relative to the GFP-negative pool. The MIP-mCherry β-cell reporter line exhibited higher insulin enrichment (~11-fold over control cells (Fig. 4B)). FACS-purified β-cells from both transgenic lines demonstrated markedly reduced expression of the non-β-cell markers glucagon and somatostatin, indicating successful purification, while retaining expression of Kv2.2 as measured by two independent qRT-PCR primer sets (Fig. 4, A and B). To study Kv2.2 expression in mouse α- and δ-cells, we used a glucagon-Cre reporter line (49) and an SST-CreER line, respectively, that were both crossed to a floxed tdTomato reporter line (Fig. 4, C and D). As expected, FACS-sorted tdTomato-positive α-cells were enriched for glucagon (16×) with low levels of somatostatin and insulin expression. FACS-sorted cells of the SST-CreER line were enriched for somatostatin (11-fold).

Although the insulin signal was absent in these cells, glucagon expression was comparable with that of the corresponding non-δ-cell fraction. Kv2.2 was detectable in the α/δ-enriched fractions but also in the non-α/δ-cell pool of cells sorted from these islets. These data suggest that Kv2.2 is not restricted to δ-cells but is expressed in all major endocrine cell types of the mouse islet, including β-cells. Studies of Kv2.2 expression within islets from other species have relied mainly on immunofluorescence (42, 57) rather than the cell sorting approach taken here, so it remains to be determined how our current findings from mouse islets translate to non-human primate and human islets.

Kv2.2 Is Regulated by Pyruvate-Isocitrate Cycling and Rescues the Inhibitory Effects of siICDc on GSIS in Primary Islet β-Cells—We next investigated whether Kv2.2 expression is reduced in primary β-cells in response to suppression of ICDc as already established for 832/13 insulinoma cells in Fig. 1. For this purpose, we treated rat islets with adenoviruses containing shRNAs specific for ICDc (Ad-siICDc) or a sequence with no known homology (Ad-siControl) (11) followed by transduction with an adenovirus containing the cDNA encoding GFP under control of the rat insulin promoter (AdRIP-GFP). Subsequently, islet cells were FACS-sorted, and qRT-PCR analyses were performed. We observed a ~2-fold enrichment in insulin expression in GFP-positive cells relative to GFP-negative cells, and Ad-siICDc treatment resulted in an 86 ± 2% reduction in ICDc mRNA levels in the GFP-positive β-cell fraction. This was accompanied by a 32 ± 10% (p < 0.001) reduction in Kv2.2 expression relative to Ad-siControl-treated β-cells (Fig. 5A). These results demonstrate that ICDc knockdown reduces
Kv2.2 expression in primary β-cells, consistent with our findings in 832/13 insulinoma cells.

Next, we investigated whether Kv2.2 overexpression can rescue the inhibitory effect of reduced ICDc expression on GSIS from intact rat islets. Ad-siICDc- and Ad-siControl-treated rat islets were co-treated with AdCMV-hKv2.2 or AdCMV-β-gal (Fig. 5B). The dose of AdCMV-hKv2.2 used in these experiments in primary rat islets was 0.35 μl. Although this dose caused a large increase in Kv2.2 mRNA levels (Fig. 5B), the dose was similar to one (0.4 μl) that caused a large increase in Kv2.2 mRNA but a moderate increase in protein overexpression in 832/13 cells (Fig. 2C). In the background of AdCMV-β-gal treatment, a 68 ± 4% reduction in ICDc mRNA levels (Fig. 5C) resulted in a ~35% impairment of insulin secretion at 16.7 mm glucose relative to untreated (p = 0.004) or AdCMV-β-gal/Ad-siControl-treated (p = 0.02) islets (Fig. 5D). Restoration of Kv2.2 expression in Ad-siICDc-treated cells (Fig. 5B) resulted in a significant increase in GSIS relative to AdCMV-β-gal/Ad-siControl, and AdCMV-hKv2.2/Ad-siControl islets (p = 0.7) (Fig. 5D). These data demonstrate that Kv2.2 overexpression fully reverses impaired GSIS caused by silencing of ICDc expression in rat islets.

**Outward K⁺ Currents Are Increased in 832/13 Cells with Reduced ICDc and Kv2.2 Expression at Stimulatory Glucose**—To determine whether our findings of a role for β-cell Kv2.2 in regulation of GSIS are related to changes in electrical activity, we performed patch clamp studies on 832/13 cells treated with...
siControl, siICDc, siKv2.1, or siKv2.2 siRNA duplexes. The experiments were performed in the presence of internal CaCl2, resulting in an estimated [Ca$^{2+}$]_free of 15 nM, allowing for activation of other K$^+$ channels in addition to Kv channels. In the presence of 2 mM glucose, siControl-treated cells exhibited current activities of 7.2 ± 2.6 pA/pF at a membrane potential of 0 mV indistinguishable from currents observed for siICDc-, siKv2.1-, and siKv2.2-treated cells (9.2 ± 3.7, 6.6 ± 1.3, and

**FIGURE 6. Interactions of Kv2.2 and Kv2.1 regulate outward K$^+$ current in β-cells.** 832/13 cells were transfected with siControl (siCont), siICDc, siKv2.1, or siKv2.2 duplexes in combination with a plasmid encoding GFP and cultured for 72 h prior to patch clamping in a Warner chamber. A, normalized current-voltage relationships at 2 mM glucose (open symbols) and 12 mM glucose (closed symbols). B, average glucose-stimulated K$^+$ current at 0 mV. Data shown are average ± S.E. (error bars) of 5–12 cells patched per condition. #, p < 0.01. @, p < 0.05. For C and D, 832/13 cells were either left untreated or treated with adenoviruses expressing β-gal, Kv2.1, Kv2.2, or combinations thereof and cultured for 24 h prior to patch clamp analyses. C, data shown are average ± S.E. (error bars) of 5–12 cells patched per condition. For C and D, 832/13 cells were either left untreated or treated with adenoviruses expressing β-gal, Kv2.1, Kv2.2, or combinations thereof and cultured for 24 h prior to patch clamp analyses. C, data shown are average ± S.E. (error bars) of 5–12 cells patched per condition. For C and D, 832/13 cells were either left untreated or treated with adenoviruses expressing β-gal, Kv2.1, Kv2.2, or combinations thereof and cultured for 24 h prior to patch clamp analyses.
Pyruvate Cycling and Kv2.2 Regulate Insulin Secretion

4.5 ± 2.0 pA/pF, respectively; p > 0.2; Fig. 6A, open symbols). At stimulatory glucose, a significant increase in current activities was seen for all conditions (closed symbols; p < 0.05). Interestingly, this glucose-stimulated increase in current activities was significantly larger for cells treated with siICDC or siKv2.2 duplexes (ΔI = 41 ± 6 and 46.7 ± 11 nA/pF at 0 mV, respectively) compared with siControl-treated cells (19 ± 8 nA/pF; p = 0.05; Fig. 6, A and B). In contrast, ΔI was unaffected by siKv2.1 treatment (13 ± 4 nA/pF; p = 0.27). Combined, these data demonstrate that at stimulatory glucose siICDC- and siKv2.2-treated cells have increased outward K⁺ current suggestive of altered membrane excitability and consistent with the impairment of GSIS observed for both of these treatments.

Effect of Kv2.1 and Kv2.2 Overexpression on Outward Kv Currents in 832/13 Cells—Given the unanticipated increase in Kv current in response to Kv2.2 suppression, we investigated the effects of Kv2.1 and Kv2.2 overexpression on Kv currents in 832/13 cells. Overexpression of Kv2.1 (28 ± 3-fold induction in Kv2.1 mRNA levels) resulted in a robust induction of Kv currents (green circles; 103.3 ± 11.3 pA/pF at a membrane potential of 0 mV) relative to AdCMV-βgal-treated (black circles; 30.7 ± 3.3 pA/pF; p < 0.001) or untreated (blue squares; 22.8 ± 2.1 pA/pF; p < 0.001) cells. In contrast, overexpression of Kv2.2 (0.2-μl dose, which caused a 59 ± 10-fold induction of mRNA levels) caused only a modest increase in Kv currents (red triangles; 41.0 ± 3.9 pA/pF at 0 mV; p < 0.01) relative to control cells (Fig. 6C). The relatively low intrinsic K⁺ channel activity attained with Kv2.2 overexpression is consistent with the low residual currents reported in islets from Kv2.1 knock-out mice (38). We also studied the effects of overexpressing Kv2.1 and Kv2.2 simultaneously. Interestingly, a 32 ± 7-fold induction in Kv2.1 mRNA expression combined with a 45 ± 9-fold induction in Kv2.2 mRNA expression resulted in a Kv current that was reduced by half compared with that observed with Kv2.1 overexpression alone (gray diamonds; 58.6 ± 9.8 pA/pF at 0 mV; p = 0.003; Fig. 6C). These findings suggest that Kv2.2 has relatively low K⁺ conductance compared with Kv2.1 and that it may also function as a negative modulator of Kv2.1 channel activity.

To further investigate the potential regulatory effect of Kv2.2 on Kv2.1, we next sought to exploit a reported preferential effect of ScTx1 as an inhibitor of Kv2.1 relative to Kv2.2 (59). We first performed a ScTx1 dose-response study in 832/13 cells with equal levels of overexpression of Kv2.1 or Kv2.2 and identified a dose of ScTx1 (25 nm) at which Kv2.1 was inhibited by ~50%, whereas Kv2.2 was not significantly inhibited at this same dose (Fig. 6D). Using this dose of ScTx1, we found that K⁺ currents recorded from 832/13 cells treated with siICDC were more sensitive to ScTx1 than siControl- or siKv2.1-treated cells studied at membrane potentials of either 0 or +30 mV (Fig. 6E). A similar trend for enhanced inhibition was noted in siKv2.2-treated cells that did not reach statistical significance relative to the siControl group. However, cells treated with siKv2.2 were significantly more susceptible to inhibition of K⁺ current by ScTx1 compared with cells treated with siKv2.1 at either 0 or 30 mV of current (Fig. 6E). Taken together, these data demonstrate that conditions that reduce Kv2.2 expression (either direct Kv2.2 silencing or in response to suppression of ICDC) remove an inhibitory effect of Kv2.2 channels on K⁺ currents in 832/13 cells, rendering the cells more sensitive to the Kv2.1-selective inhibitor.

To investigate whether the foregoing results could be related to an ability of Kv2.1 and Kv2.2 to form heterodimers in β-cells as has been shown in neuronal cells (60), we performed co-immunoprecipitation studies. We prepared extracts of 832/13 cells and immunoprecipitated with an antibody specific for Kv2.2 followed by immunoblotting with antibody for Kv2.2 or Kv2.1. Note that this experiment was performed with non-virus-treated 832/13 cells to study interactions of their endogenous Kv2.1 and Kv2.2 proteins. Both Kv2.2 and Kv2.1 were clearly detected in samples immunoprecipitated with the Kv2.2 antibody but not in samples treated with a control IgG (Fig. 6F). We also performed the converse experiment of immunoprecipitation with an antibody for Kv2.1 followed by immunoblotting for Kv2.1 and Kv2.2. Again, both Kv2.2 and Kv2.1 were clearly present in samples immunoprecipitated with the Kv2.1-specific antibody (Fig. 6F). In aggregate, the data shown in Fig. 6 are consistent with a model in which Kv2.2 engages in a physical interaction with Kv2.1 in β-cells, and that engagement of Kv2.1 in such complexes suppresses its ability to create Kv current. The model further holds that this suppressive function of Kv2.2 is controlled in part by pyruvate-isocitrate cycling activity.

DISCUSSION

Both type 1 and type 2 diabetes are syndromes of insulin deficiency, although the origins of the diseases are different. In type 1 diabetes, β-cells are destroyed by the host immune system (61). Type 2 diabetes is associated with impaired control of insulin secretion in response to nutrients coupled with gradual depletion of β-cell mass mainly due to increased apoptosis and inadequate β-cell regeneration (62). A clearer understanding of basic β-cell function is critical to develop surrogate cells for insulin replacement therapies for type 1 diabetes and for expansion of therapeutic options for treatment of type 2 diabetes.

Previously, we have demonstrated that maintaining flux through the pyruvate-isocitrate pathway is essential for normal GSIS (8, 10, 11, 23), but the molecular mediators of this effect were not identified. NADPH is a potential second messenger generated by the pyruvate-isocitrate cycle, and one study has suggested that NADPH can inactivate Kv channels (44), possibly serving to slow membrane repolarization, thereby allowing the effects of suppression of KᵥATC channels to be sustained. To test a possible relationship among pyruvate-isocitrate cycling, Kv channels, and insulin secretion, we measured expression levels of Kv2 channels in cells exhibiting reduced pyruvate-isocitrate activity and impaired GSIS. Surprisingly, we found that cells with reduced ICDC and CIC expression have decreased rather than increased Kv2.2 mRNA expression with no effect on expression of Kv2.1. Impairment of GSIS caused by suppression of ICDC expression was rescued by re-expression of Kv2.2 but not Kv2.1. Importantly, these responses to suppression of pyruvate-isocitrate cycling were observed in primary rat islets as well as in the 832/13 insulinoma cell line. Exposure of 832/13 cells to chronic elevations of fatty acids, another model of impaired GSIS and dysregulated pyruvate cycling (6), also caused a decrease in Kv2.2 mRNA levels. More-
over, targeted knockdown of Kv2.2 impaired GSIS. When we measured Kv currents using patch clamp techniques in 832/13 cells with reduced ICDc or Kv2.2 expression, we observed increases in outward Kv currents at stimulatory glucose concentrations relative to control cells. In contrast, Kv2.1 silencing caused a trend to increase GSIS with no measureable effect on Kv current.

We interpret our findings to suggest a novel modulatory role of pyruvate-isocitrate cycling and Kv2.2 in control of electrical activity and GSIS in islet β-cells. In this model, pyruvate-isocitrate cycling serves to maintain levels of Kv2.2 expression that are sufficient to provide tonic suppression of Kv2.1 function. In support of such a model, co-overexpression of Kv2.1 and Kv2.2 in β-cells resulted in reduced Kv current compared with overexpression of Kv2.1 alone. Moreover, suppression of Kv2.2 expression either by direct knockdown or in response to knockdown of ICDc resulted in greater sensitivity of 832/13 cells to inhibition of K+ currents by the Kv2.1-selective inhibitor ScTx1, supporting the proposed suppressor function of endogenous Kv2.2 channels. Also consistent with the model, co-immunoprecipitation experiments demonstrated an interaction of the endogenous Kv2.1 and Kv2.2 channels. This interaction could reflect formation of a Kv2.1-Kv2.2 channel complex as supported by our functional data and by studies in oocytes and pyramidal neurons (60, 63). In both of the prior studies, co-expression of a dominant negative Kv2.2 subunit with wild-type Kv2.1 or Kv2.2 channels in oocytes resulted in reduced Kv channel activity, fully supporting a model of formation of heteromultimeric complexes (60, 63). However, in one of those studies (60), co-overexpression of native Kv2.1 and Kv2.2 channels in oocytes resulted in increased K+ current relative to expression of either channel alone. We have no immediate explanation for this apparent discrepancy but note that our study was performed in the relevant cell type, the islet β-cell, rather than in oocytes and that our model of a suppressive effect of Kv2.2 is supported by the four distinct lines of evidence summarized above.

It is important to note that other models are also possible. Kv2.1 and Kv2.2 are highly homologous proteins in their N-terminal regions but diverge substantially at their C termini. The different C termini of the two proteins allow them to interact differentially with other proteins. For example, Kv2.2 appears to be guided to the plasma membrane in part by the β-subunit Kvβ4, whereas this mechanism is not involved in transport of Kv2.1 (64). Thus, it is possible that the negative impact of Kv2.2 suppression on GSIS is indirect, regulated by increases in the free pool of β-subunits that can now interact with other proteins, including other ion channels.

MacDonald and co-workers (65, 66) have recently described novel biological roles of Kv2.1 in islet cells. They demonstrate that overexpression of Kv2.1 augments insulin exocytosis as measured by membrane capacitance measurements in patch-clamped islet cells. Because these experiments are performed under depolarized conditions, this effect of Kv2.1 is independent of its effects on electrical function. The potentiating effect of Kv2.1 appears to be mediated by its interaction with the SNARE protein syntaxin-1 via a specific motif in the Kv2.1 C-terminal region. Deletion of that interaction domain or interference with the interaction by delivery of a “decoy” peptide reverses the activating effect of Kv2.1 on exocytosis, and the interfering peptide also impairs GSIS in intact islets. Other recent studies have demonstrated that Kv channels in islets are modified by SUMOylation, and this modification may participate in regulating the Kv2.1/syntaxin-1 interaction (66, 67). Our finding of impairment in GSIS in response to knockdown of Kv2.2 does not seem to fit with the syntaxin-1 model of Kv2.1 function because one might anticipate that a decrease in Kv2.2 would create a larger pool of free Kv2.1 for interaction with syntaxin-1. Further studies will be required to fully understand the impact of Kv2.2 suppression on functional Kv channel assembly and stability, interaction of channels with syntaxin-1 and potentially other SNARE proteins, and modification of the channels by SUMOylation and other post-translational events.

Our study provides new information about expression of Kv2.2 in the various endocrine cell types of the pancreatic islet. We were led to investigate this issue based on reports that Kv2.2 is expressed primarily in β-cells (42, 57) and another recent study showing that global knock-out of Kv2.1 in transgenic mice results in enhanced GSIS in isolated islets and that Ad-siRNA-mediated knockdown of Kv2.2 in mouse islets enhances somatostatin but not insulin secretion (68). The latter findings should be interpreted with caution as mouse islets are reported to be refractory to penetration of recombinant adenoviruses to the β-cell core relative to rat islets (48, 52), possibly explaining the absence of an effect of Kv2.2 knockdown on insulin secretion in the setting of the mouse islet. The current study used FACS-sorted mouse islet cells to demonstrate clear expression of Kv2.2 in β-cell-, α-cell-, and δ-cell-enriched cell pools. Moreover, sorting of β-cells from rat islets with a RIP-GFP adenovirus allowed us to demonstrate that suppression of ICDc in β-cells causes a decrease in β-cell Kv2.2 expression, resulting in impaired GSIS, and that this defect is rescued by re-expression of Kv2.2. Taken together, our findings demonstrate significant expression of Kv2.2 in β-cells as well as a β-cell-autonomous effect of pyruvate-isocitrate cycling to regulate Kv2.2 and GSIS. Consistent with these findings, Kv2.2 is clearly expressed in our well differentiated INS-1-derived β-cell line, 832/13.

siRNA-mediated suppression of either of two enzymes involved in the pyruvate-isocitrate cycle, CIC or ICDc, resulted in reduced expression of Kv2.2 but not Kv2.1 at the RNA level; a similar response is observed upon chronic culture of islet cells with elevated free fatty acids. The mechanisms involved in the control of Kv2.2 transcript levels remain to be resolved. The temporal scale of these effects (measured over several days of siRNA treatment or fatty acid culture) and the known temporal dynamics of changes in gene expression (generally measured in hours rather than minutes) suggest that regulation of Kv2.2 expression by pyruvate-isocitrate cycling is an adaptive mechanism rather than an acute event in control of GSIS. The possibility remains that other signals generated by pyruvate-isocitrate cycling activity, including NADPH production via the cytosolic ICDc reaction, could play a direct role in acute regulation of GSIS, and this is a subject of ongoing investigation.

In conclusion, the current study identifies a novel link between a β-cell metabolic pathway and Kv channels. Impor-
tantly, this pathway becomes impaired in response to chronic exposure of islets to high fat, a model often used as a surrogate for the “nutritional overload” experienced on the path to type 2 diabetes. Our findings suggest that interventions that reactivate pyruvate-isocitrate cycling or that maintain Kv2.2 expression may be of benefit for reversing islet dysfunction of diabetes.

REFERENCES
1. Ashcroft, F. M. (2005) ATP-sensitive potassium channelopathies: focus on insulin secretion. J. Clin. Invest. 115, 2047–2058
2. Drews, G., Krippert-Drews, P., and Düfer, M. (2010) Electrophysiology of islet cells. Adv. Exp. Med. Biol. 654, 115–163
3. Komatsu, M., Sato, Y., Aizawa, T., and Hashizume, K. (2001) K$_{ATP}$ channel-independent glucose action: an elusive pathway in stimulus-secretion coupling of pancreatic β-cell. Endocr. J. 48, 275–288
4. Sato, Y., Anello, M., and Henquin, J. C. (1992) Evidence that glucose can control insulin release independently from its action on ATP-sensitive K$^+$ channels in mouse B cells. J. Clin. Invest. 89, 1288–1295
5. Boucher, A., Lu, D., Burgess, S. C., Telemaque-Potts, S., Jensen, M. V., Mulder, H., Unger, R. H., Sherry, A. D., and Newgard, C. B. (2004) Biochemical mechanism of lipid-induced impairment of glucose-stimulated insulin secretion. J. Biol. Chem. 279, 27263–27271
6. Jensen, M. V., Joseph, J. W., Ilkayeva, O., Palmieri, F., Alarcon, C., Rhodes, C. J., and Newgard, C. B. (2006) The mitochondrial oxoglutarate carrier plays a regulatory role in glucose-stimulated insulin secretion. J. Biol. Chem. 281, 22342–22351
7. Lu, D., Mulder, H., Zhao, P., Burgess, S. C., Chen, M. V., Kamzolova, S., Newgard, C. B., and Sherry, A. D. (2002) ATP-citrate lyase or fatty acid synthase is not required for glucose-stimulated insulin secretion. J. Biol. Chem. 277, 16530–16537
8. Jensen, M. V., Joseph, J. W., Ronnebaum, S. M., Becker, T. C., Sherry, A. D., and Newgard, C. B. (2010) The mitochondrial 2-oxoglutarate carrier is part of a metabolic pathway that mediates glucose- and glutamine-stimulated insulin secretion. J. Biol. Chem. 285, 16530–16537
9. Ronnebaum, S. M., Ilkayeva, O., Burgess, S. C., Joseph, J. W., Lu, D., Stevens, R. D., Becker, T. C., Sherry, A. D., Newgard, C. B., and Jensen, M. V. (2006) A pyruvate cycling pathway involving cytosolic NADP-dependent isocitrate dehydrogenase regulates glucose-stimulated insulin secretion. J. Biol. Chem. 281, 30593–30602
10. Ronnebaum, S. M., Jensen, M. V., Hohmeier, H. E., Burgess, S. C., Zhou, Y. P., Qian, S., MacNeil, D., Howard, A., Thornberry, N., Ilkayeva, O., Lu, D., Sherry, A. D., and Newgard, C. B. (2008) Silencing of cytosolic or mitochondrial isofoms of malic enzyme has no effect on glucose-stimulated insulin secretion from rodent islets. J. Biol. Chem. 283, 28909–28917
11. Joseph, J. W., Odegaard, M. L., Ronnebaum, S. M., Burgess, S. C., Muehlbauer, J., Sherry, A. D., and Newgard, C. B. (2007) Normal flux through ATP-citrate lyase or fatty acid synthase is not required for glucose-stimulated insulin secretion. J. Biol. Chem. 282, 31592–31600
12. Huypens, P., Pillai, R., Sheinin, T., Schaefer, S., Huang, M., Odegaard, M. L., Ronnebaum, S. M., Wettig, S. D., and Joseph, J. W. (2011) The dicarboxylate carrier plays a role in mitochondrial malate transport and in the regulation of glucose-stimulated insulin secretion from rat pancreatic β cells. Diabetologia 54, 135–145
13. Farfari, S., Schulz, V., Corkey, B., and Prentki, M. (2000) Glucose-regulated anaplerosis and cataplerosis in pancreatic β-cells: possible implication of a pyruvate/citrate shuttle in insulin secretion. Diabetes 49, 718–726
14. Pongratz, R. L., Kibbey, R. G., Shulman, G. L., and Cline, G. W. (2007) Cytosolic and mitochondrial malic enzyme isoforms differentially control insulin secretion. J. Biol. Chem. 282, 200–207
15. Cline, G. W., Lepine, R. L., Papas, K. K., Kibbey, R. G., and Shulman, G. I. (2004) 13C NMR isotopomer analysis of anaplerotic pathways in INS-1 cells. J. Biol. Chem. 279, 44370–44375
16. Guay, C., Madiraju, S. R., Aumaïs, A., Joly, E., and Prentki, M. (2007) A role for ATP-citrate lyase, malic enzyme, and pyruvate/citrate cycling in glucose-induced insulin secretion. J. Biol. Chem. 282, 35657–35665
17. Fransson, U., Rosengren, A. H., Schuit, F. C., Renström, E., and Mulder, H. (2006) Anaplerosis via pyruvate carboxylase is required for the fuel-induced rise in the ATP/ADP ratio in rat pancreatic islets. Diabetologia 49, 1578–1586
18. Schuit, F., De Vos, A., Farfari, S., Moens, K., Pipeleers, D., Brun, T., and Prentki, M. (1997) Metabolic fate of glucose in purified islet cells. Glucose-regulated anaplerosis in β cells. J. Biol. Chem. 272, 18572–18579
19. Brun, T., Roche, E., Assimacopoulos-Jeannet, F., Corkey, B. E., Kim, K. H., and Prentki, M. (1996) Evidence for an anaplerotic/ malonyl-CoA pathway in pancreatic β-cell nutrient signaling. Diabetes 45, 190–198
20. MacDonald, M. J., Fahien, L. A., Alarcon, C., Rhodes, C. J., and Newgard, C. B. (2006) The mitochondrial citrate/isocitrate carrier plays a regulatory role in glucose-stimulated insulin secretion. J. Biol. Chem. 281, 35624–35632
21. Jacobson, D. A., and Philipson, L. H. (2007) Action potentials and insulin secretion: new insights into the role of Kβ channels. Diabetes Obes. Metab. 9, Suppl. 2, 89–98
22. Kerschensteiner, D., and Stocker, M. (1999) Heteromeric assembly of Kvβ1.2 with Kv9.3: effect on the state dependence of inactivation. Biophys. J. 77, 248–257
23. Sano, Y., Mochizuki, S., Miyake, A., Kitada, C., Inamura, Y., Yokoi, H., Nozawa, K., Matsushima, H., and Furuchi, K. (2002) Molecular cloning and characterization of Kvβ3.6, a novel regulatory subunit for voltage-gated K$^+$ channel Kvβ1.2. FEBS Lett. 512, 230–234
24. Rettig, J., Heinemann, S. H., Wunder, F., Lorca, C., Parcej, D. N., Dolly, J. O., and Pongs, O. (1994) Inactivation properties of voltage-gated K$^+$ channels altered by expression of β-subunit. Nature 369, 289–294
25. Chouinard, S. W., Lu, F., Ganetzky, B., and Macdonald, M. J. (2000) Evidence for voltage-gated potassium channel β-subunits with oxidoreductase motifs in human and rodent pancreatic β cells. Receptors Channels 7, 237–243
26. Pongs, O., Leicher, T., Berger, M., Roep, J., Bähring, W., Dray, D., Giese, K. P., Silva, A. J., and Storm, J. F. (1999) Functional and molecular aspects of voltage-gated K$^+$ channel β subunits. Ann. N.Y. Acad. Sci. 868, 344–355
27. Hermansteyn, T. O., Khira, Y., Misono, K., Deitcher, A., Yanagawa, Y., and Misonou, H. (2010) Immunolocalization of the voltage-gated potassium channel Kvβ2.2 in GABAergic neurons in the basal forebrain of rats and mice. J. Comp. Neurol. 518, 4289–4310
28. Jindal, H. K., Folco, E. J., Liu, G. X., and Koren, G. (2008) Posttranslational modification of voltage-dependent potassium channel Kv1.5: COOH-terminal palmitoylation modulates its biological properties. Am. J. Physiol. Heart Circ. Physiol. 294, H2012–H2021
29. Boehmer, C., Laufer, J., Jeyaraj, S., Klaus, F., Lindner, R., Lang, F., and Palmada, M. (2008) Modulation of the voltage-gated potassium channel Kv1.5 by the SGK1 protein kinase involves inhibition of channel ubiquitination. Cell. Physiol. Biochem. 22, 591–600
30. Nitabach, M. N., Llamas, D. A., Thompson, J. I., Collins, K. A., and Holmes, T. C. (2002) Phosphorylation-dependent and phosphorylation-independent modes of modulation of shaker family voltage-gated potassium channels by SRC family protein tyrosine kinases. J. Neurosci. 22, 7913–7922
31. Roe, M. W., Worley, J. F., 3rd, Mittal, A. A., Kuznetsov, A., DasGupta, S., Mertz, R. J., Witherspoon, S. M., 3rd, Blair, N., Lancaster, M. E., McIntyre, M. S., Shehee, W. R., Dukes, I. D., and Philipson, L. H. (1996) Expression
and function of pancreatic β-cell delayed rectifier K⁺ channels. Role in stimulus-secretion coupling. *J. Biol. Chem.* 271, 32241–32246.

35. MacDonald, P. E., Sewing, S., Wang, J., Joseph, J. W., Smukler, S. R., Sakellaropoulos, G., Wang, J., Saleh, M. C., Chan, C. B., Tsushima, R. G., Salapatek, A. M., and Wheeler, M. B. (2002) Inhibition of Kv2.1 voltage-dependent K⁺ channels in pancreatic β-cells enhances glucose-dependent insulin secretion. *J. Biol. Chem.* 277, 44938–44945.

36. Herrington, J., Zhou, Y. P., Bugianesi, R. M., Dulski, P. M., Feng, Y., Warren, V. A., Smith, M. M., Kohler, M. G., Garsky, V. M., Sanchez, M., Wagner, M., Raphaelli, K., Banerjee, P., Ahaghotu, C., Wunderler, D., Priest, B. T., Mehl, J. T., Garcia, M. L., McM anus, O. B., Kaczorowski, G. J., and Slaughter, R. S. (2006) Blockers of the delayed-rectifier potassium current in pancreatic β-cells enhance glucose-dependent insulin secretion. *Diabetes* 55, 1034–1042.

37. Tamarina, N. A., Kuznetsova, A., Fridlyand, L. E., and Philipson, L. H. (2005) Delayed-rectifier (Kv2.1) regulation of pancreatic β-cell calcium responses to glucose: inhibitor specificity and modeling. *Am. J. Physiol. Endocrinol. Metab.* 289, E578–E585.

38. Jacobson, D. A., Kuznetsova, A., Lopez, J., P. K., Kash, S., Ammälä, C. E., and Philipson, L. H. (2007) Kv2.1 alteration alters glucose-induced islet electrical activity, enhancing insulin secretion. *Cell Metab.* 6, 229–235.

39. Herrington, J., Sanchez, M., Wunderler, D., Yan, L., Bugianesi, R. M., Dick, J. E., Clark, S. A., Brochu, R. M., Priest, B. T., Kohler, M. G., and McManus, O. B. (2005) Biophysical and pharmacological properties of the voltage-gated potassium current of human pancreatic β-cells. *J. Physiol.* 567, 159–175.

40. Braun, M., Ramcharaya, R., Bengtsson, M., Zhang, Q., Karanauskaite, J., Partridge, C., Johnson, P. R., and Rorsman, P. (2008) Voltage-gated ion channels in human pancreatic β-cells: electrophysiological characterization and role in insulin secretion. *Diabetes* 57, 1618–1628.

41. Pedersen, M. G. (2010) A biophysical model of electrical activity in human β-cells. *Biophys. J.* 99, 3200–3207.

42. Wolf-Goldberg, T., Michaelevski, I., Sheu, L., Gaisano, H. Y., Chikvashvili, D., and Lotan, I. (2006) Target soluble N-ethylmaleimide-sensitive factor attachment protein receptors (t-SNAREs) differently regulate activation and inactivation gating of Kv2.2 and Kv2.1. Implications on pancreatic islet cell Kv channels. *J. Physiol.* 576, 647–653.

43. Ivarssoin, R., Quintens, R., Dejonghe, S., Tsukamoto, K., in ’t Veld, P., Renström, E., and Schuit, F. C. (2005) Redox control of excytosis: regulatory role of NADPH, thioredoxin, and glutaredoxin. *Diabetes* 54, 2132–2142.

44. MacDonald, P. E., Salapatek, A. M., and Wheeler, M. B. (2003) Temperature and redox state dependence of native Kv2.1 currents in rat pancreatic β-cells. *J. Physiol.* 546, 647–653.

45. Asfari, M., Janicik, D., Meda, P., Li, G., Halban, P. A., and Wollheim, C. B. (1992) Establishment of 2-mercaptoethanol-dependent differentiated islet-secreting cell lines. *Endocrinology* 130, 167–178.

46. Hohmeier, H. E., Mulder, H., Chen, G., Henkel-Rieger, R., Prentki, M., and Philipson, L. H. (2007) Kv2.1 ablation alters glucose-induced islet electrical activity, enhancing insulin secretion. *Cell Metab.* 6, 229–235.

47. Kihira, Y., Hermanstyne, T. O., and Misonou, H. (2010) Formation of pancreatic β-cell calcium channel-dependent and -independent glucose-stimulated insulin secretion. *Diabetes* 59, 424–430.

48. Hara, M., Wang, X., Kawamura, T., Bindokas, V. P., Dixon, R. F., Alcoser, S. Y., Magnusson, M. A., and Bell, G. I. (2003) Transgenic mice with green fluorescent protein-labeled pancreatic islet cell Kv channels. Role in stimulus-secretion coupling. *Diabetes* 52, 1590–1597.

49. Li, X. N., Herrington, J., Petrov, A., Ge, L., Eiermann, G., Xiong, Y., Jensen, O. B. (2005) Biophysical and pharmacological properties of the voltage-gated potassium current of human pancreatic β-cells. *J. Physiol.* 567, 159–175.

50. Rieck, S., White, P., Schug, J., Fox, A. J., Smirnova, O., Gao, N., Gupta, R. K., Wang, Z. V., Scherer, P. E., Keller, M. P., Attie, A. D., and Kaestner, K. H. (2009) The transcriptional response of the islet to pregnancy in mice. *Mol. Endocrinol.* 23, 1702–1712.

51. Escoubas, P., Diochot, S., Célérier, M. L., Nakajima, T., and Lodzinski, M. (2002) Novel tarantula toxins for subtypes of voltage-dependent potassium channels in the Kv2 and Kv4 subfamilies. *J. Physiol.* 546, 48–57.

52. Blaine, J. T., and Ribera, A. B. (1998) Heteromultimeric potassium channels formed by members of the Kv2 subfamily. *J. Neurosci.* 18, 9585–9593.

53. van Bellen, T. L., Coppieters, K. T., and van Herrath, M. G. (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. *Physiol. Rev.* 91, 79–118.

54. Muioio, D. M., and Newgard, C. B. (2008) Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes. *Nat. Rev. Mol. Cell Biol.* 9, 193–205.

55. Kihira, Y., Hermanstyne, T. O., and Misonou, H. (2010) Formation of heteromeric Kv2 channels in mammalian brain neurons. *J. Biol. Chem.* 285, 15048–15055.

56. Fink, M., Duprat, F., Lesage, F., Heurtets, C., Romey, G., Barhanin, J., and Lazdunski, M. (1996) A new K⁺ channel subunit to specifically enhance Kv2.2 (CDRK) expression. *J. Biol. Chem.* 271, 26341–26348.

57. Dai, X. Q., Manning Fox, J. E., Chikvashvili, D., Casimir, M., Plummer, G., Hajmire, C., Spigelman, A. F., Kin, T., Singer-Lahat, D., Yang, Y., Shapiro, A. M., Gaisano, H. Y., Lotan, I., and Macdonald, P. E. (2012) The voltage-dependent potassium channel subunit Kv2.1 regulates insulin secretion from rodent and human islets independently of its electrical function. *Diabetologia* 55, 1709–1720.

58. Dai, X. Q., Plummer, G., Casimir, M., Yang, Y., Hajmire, C., Gaisano, H. Y., Manning Fox, J. E., and MacDonald, P. E. (2011) SUMOylation regulates insulin exocytosis downstream of secretory granule docking in rodents and humans. *Diabetes* 60, 838–847.

59. Dai, X. Q., Kolic, J., Marchi, P., Spione, S., and Macdonald, P. E. (2009) SUMOylation regulates Kv2.1 and modulates pancreatic β-cell excitability. *J. Cell Sci.* 122, 775–779.

60. Li, X. N., Herrington, J., Petrov, A., Eiermann, G., Xiong, Y., Jensen, M. V., Hohmeier, H. E., Newgard, C. B., Garcia, M. L., Wagner, M., Zhang, B. B., Thornberry, N. A., Howard, A. D., Kaczorowski, G. J., and Zhou, Y. P. (2013) The roles of voltage-gated potassium channels Kv2.1 and Kv2.2 in the regulation of insulin and somatostatin release from pancreatic islets. *J. Pharmacol. Exp. Ther.* 344, 407–416.